Adjuvant nivolumab after chemoradiotherapy and resection for patients with esophageal cancer: A real‐world matched comparison of overall survival

作者
Rob H.A. Verhoeven,Steven C. Kuijper,Marije Slingerland,Bas P. L. Wijnhoven,Mark I. van Berge Henegouwen,Peter S.N. van Rossum,Sarah Derks,Bianca Mostert,Nadia Haj Mohammad,Hanneke W. M. van Laarhoven
出处
期刊:International Journal of Cancer [Wiley]
标识
DOI:10.1002/ijc.70168
摘要

Abstract The Checkmate‐577 trial showed a significant disease‐free and a non‐significant overall survival benefit for nivolumab compared to placebo in esophageal or gastroesophageal junction (GEJ) cancer patients with residual disease after neoadjuvant chemoradiotherapy (nCRT) and resection. Real‐world overall survival (OS) data has not yet been presented. The aim of this study was to evaluate OS of patients treated with or without adjuvant nivolumab in a nationwide real‐world matched comparison.For this study, patients diagnosed with non‐metastatic esophageal or GEJ cancer in 2020–2023 who had residual pathological disease after nCRT and resection were selected from the Netherlands Cancer Registry. 333 patients received treatment with adjuvant nivolumab. From the period before the introduction of nivolumab, 486 patients were selected who received nCRT and resection alone. Propensity score trimming and nearest neighbor matching were used to create two well‐balanced groups of 311 patients per treatment group. Median follow‐up time was 24.4 months and 31.4 months for patients treated with and without adjuvant nivolumab, respectively. The 2‐year OS was 66.8% (95% confidence interval [CI]: 61.6%–72.44%) and 58.8% (95% CI: 53.5%–64.5%) for the groups with and without nivolumab, respectively (log‐rank p = 0.024), hazard ratio: 0.75, 95% CI: 0.60–0.97 ( p = 0.024). In conclusion, this matched real‐world study showed an OS in favor of patients treated with nivolumab compared to patients without nivolumab. This represents the first report on a real‐world OS benefit in this setting. As follow‐up and the number of events are still limited, these analyses should be interpreted with caution and updated in the forthcoming years.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
StarXG完成签到,获得积分10
刚刚
1秒前
wqwq69完成签到,获得积分10
1秒前
1秒前
liliang316完成签到,获得积分10
1秒前
挚友发布了新的文献求助20
1秒前
熊博士完成签到,获得积分10
1秒前
感谢无辜的傲芙转发科研通微信,获得积分50
2秒前
whyme完成签到,获得积分10
2秒前
Vision完成签到,获得积分10
2秒前
nihao完成签到,获得积分10
2秒前
了凡完成签到,获得积分10
3秒前
本尼脸上褶子完成签到 ,获得积分10
3秒前
天天快乐的应助被挽风风风风采纳,获得10
3秒前
张乐完成签到,获得积分10
3秒前
一叶孤舟完成签到,获得积分10
4秒前
xzx完成签到,获得积分10
4秒前
4秒前
跳跃指甲油完成签到 ,获得积分10
4秒前
感谢干净沉鱼转发科研通微信,获得积分50
4秒前
TQ完成签到,获得积分10
4秒前
淡然胡萝卜完成签到,获得积分10
4秒前
万柏祺完成签到,获得积分10
5秒前
素雅完成签到,获得积分10
5秒前
简单的一一完成签到,获得积分10
6秒前
蔗不对吧完成签到,获得积分10
6秒前
聂落雁完成签到,获得积分10
6秒前
无患子完成签到,获得积分10
6秒前
感谢梁梁梁梁转发科研通微信,获得积分50
7秒前
huairenzhao完成签到 ,获得积分10
7秒前
7秒前
九日完成签到,获得积分10
7秒前
wm完成签到,获得积分10
7秒前
学习通完成签到,获得积分10
8秒前
刘亚军完成签到 ,获得积分10
8秒前
叁月参完成签到,获得积分10
8秒前
万物生完成签到,获得积分10
8秒前
虚幻沛文完成签到 ,获得积分10
8秒前
锅锅完成签到,获得积分10
9秒前
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173463
求助须知:如何正确求助?哪些是违规求助? 9565690
关于积分的说明 21781315
捐赠科研通 7767647
什么是DOI,文献DOI怎么找? 3431597
关于科研通互助平台的介绍 2555855
邀请新用户注册赠送积分活动 2476808